Find a Doctor

Dr. Gideon Morris Hirschfield

Children's Liver Disease Foundation

Bio


Dr. Hirschfield is a global expert in Sclerosing Cholangitis. He has been an author on 248 peer reviewed articles in the past 15 years. In particular, he has been an author on 80 peer reviewed articles regarding Sclerosing Cholangitis.

Contact

GB

Latest Advances


  • Condition: Primary Biliary Cholangitis (PBC)
  • Journal: Journal of hepatology
  • Treatment Used: Preventative Ursodeoxycholic Acid (UDCA) after Transplantation
  • Number of Patients: 780
  • Published —
This study tested the safety and efficacy of using UDCA after transplantation to treat patients with PBC.
  • Condition: Primary Sclerosing Cholangitis (PSC)
  • Journal: Journal of hepatology
  • Treatment Used: Obeticholic Acid (OCA)
  • Number of Patients: 76
  • Published —
This study investigated the safety and effectiveness of obeticholic acid (OCA) in the treatment of primary sclerosing cholangitis (liver disease; PSC).
  • Condition: Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
  • Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • Treatment Used: Vedolizumab
  • Number of Patients: 102
  • Published —
The study researched the outcomes of Vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases.
  • Condition: Primary Biliary Cholangitis
  • Journal: Journal of hepatology
  • Treatment Used: Ursodeoxycholic Acid Therapy
  • Number of Patients: 3902
  • Published —
In this study, researchers evaluated the outcomes of treating primary biliary cholangitis with ursodeoxycholic acid therapy.
  • Condition: Primary Sclerosing Cholangitis
  • Journal: Alimentary pharmacology & therapeutics
  • Treatment Used: Ileal Pouch-Anal Anastomosis
  • Number of Patients: 240
  • Published —
This study tested the safety and efficacy of using ileal pouch-anal anastomosis to treat patients with primary sclerosing cholangitis following a liver transplant.
  • Condition: Primary biliary cholangitis
  • Journal: Lancet (London, England)
  • Treatment Used: Ileal bile acid transporter inhibitor GSK2330672
  • Number of Patients: 22
  • Published —
This study investigated the efficacy and safety of ileal bile acid transporter inhibitor GSK2330672 in primary biliary cholangitis.

Clinical Trials


All Publications
View All


  • Sponsor: American Association for the Study of Liver Diseases (AASLD)
  • Event Name: American Association for the Study of Liver Diseases: The Liver Meeting 2020
  • Published —
QUALITY OF LIFE AMONG PATIENTS WITH PRIMARY BILIARY CHOLANGITIS DURING CANADA’S STATE OF EMERGENCY RESPONSE TO COVID‐19

Contact

GB

Insurance

Contact them to find out if they accept your insurance plan.